A competing‐risks nomogram for sarcoma‐specific death following local recurrence
- 29 October 2003
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 22 (22) , 3515-3525
- https://doi.org/10.1002/sim.1574
Abstract
The majority of staging systems focus on the definition of stage, and, therefore, prediction of prognosis. In the current era of clinical trial research, it has become apparent that the clinical stage alone is not sufficient to assess patient risk of treatment failure. As the number of biological markers increases, our ability to partition the traditional disease classification system improves, and our ability to predict patient success continues to increase. One approach to quantifying individual patient risk is through the nomogram. Nomograms are graphical representations of statistical models, which provide the probability of treatment outcome based on patient‐specific covariates. We will focus on the use of the nomogram when the response variable is time to failure and there are multiple, possibly dependent, competing causes of failure. In this setting, estimation of the failure probability through direct application of the Cox proportional hazards model provides the probability of failure (for example, death from cancer) assuming failure from a dependent competing cause will not occur. In many clinical settings this is an unrealistic assumption. The purpose of this study is to illustrate the use of the conditional cumulative incidence function for providing a patient‐specific prediction of the probability of failure in the setting of competing risks. A competing risks nomogram is produced to estimate the probability of death due to sarcoma for patients who have already developed a local recurrence of their initially treated soft‐tissue sarcoma. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Regression modeling of competing crude failure probabilitiesBiostatistics, 2001
- Repeat resection of pulmonary metastases in patients with soft-tissue sarcomaJournal of the American College of Surgeons, 2000
- Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer IncidenceJNCI Journal of the National Cancer Institute, 1999
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Pulmonary Metastases From Soft Tissue SarcomaAnnals of Surgery, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORSStatistics in Medicine, 1996
- Development and Treatment of Pulmonary Metastases in Adult Patients with Extremity Soft Tissue SarcomaAnnals of Surgery, 1993
- Kaplan—meier, marginal or conditional probability curves in summarizing competing risks failure time data?Statistics in Medicine, 1993
- Approximate Case Influence for the Proportional Hazards Regression Model with Censored DataPublished by JSTOR ,1984